BSBE(SZ:300406) Sou Hu Cai Jing·2025-07-24 09:58Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Jiukang Biological Technology Co., Ltd., indicating a decline in revenue and profit in the latest quarterly report [1][2] - As of July 24, Jiukang's stock closed at 14.75 yuan, with a PE ratio of 17.46, marking a 64-day low, and a total market capitalization of 8.648 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning Jiukang at 38th among its peers [1][2] Group 2 - In the first quarter of 2025, Jiukang reported revenue of 320 million yuan, a year-on-year decrease of 18.81%, and a net profit of 83.2575 million yuan, down 30.99%, with a gross margin of 80.84% [1] - The company specializes in biochemical diagnostics, blood coagulation testing, blood type testing, and tumor pathology diagnostics, with key products including in vitro diagnostic reagents and instruments [1] - As of the first quarter of 2025, seven institutions held shares in Jiukang, with a total of 9.9565 million shares valued at 141 million yuan [1]